Neurocrine Continues Freefall

Analysts downgraded Neurocrine Biosciences Inc. (NBIX) after the Food and Drug Administration yesterday delayed approval of the company's insomnia treatment indiplon. Shares of Neurocrine extended losses from yesterday by falling another $1.04 to close at $19.72 while Dov Pharmceutical Inc. (DOVP) stock lost another 24 cents to close at $2.78. Dov licensed indiplon to Neurocrine.